Replacement Prospectus
Released
Released
Announcement PDF
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Replacement
Prospectus
ReNerve Limited
ACN 614 848 216
Offer of up to 35,000,000 Shares at
an issue price of $0.20 per Share to
raise up to $7,000,000 (before costs
and expenses of the Offer).
The Offer is subject to a minimum
subscription of 25,000,000 Shares
to raise $5,000,000 (before costs
and expenses of the Offer).
Lead Manager
This document is important.
You should read it in its entirety.
You should consult your stockbroker,
accountant or other professional
adviser before deciding whether
to invest in Shares.
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Important Notice
This Prospectus is an important document and requires your
prompt attention. You should read it carefully. It is important that
you consider the risk factors (see section 6) before deciding on your
course of action as these could affect the financial performance
of ReNerve Limited (ReNerve or Company).
Offer
The Offer contained in this Prospectus is an invitation to acquire
Shares in the Company.
Lodgement and listing
This Replacement Prospectus (Prospectus) is dated 29 October 2024
and a copy of this Prospectus was lodged with ASIC on that date.
It contains certain changes to and replaces the Prospectus dated
16 October 2024. In summary, amendments were made to:
• clarify that the Company’s ability to continue as a going concern
is not contingent on successful completion of the Offer;
• highlight certain risks associated with an investment in the
Company in the Chairman’s letter (including risks relating
to intellectual property);
• expand on the summaries of certain material contracts
(see section 10);
• clarify elements of the Company’s proposed use of funds
(including working capital and operating expenses) and the
Company’s costs of the Offer (see sections 4.10 and
11.8 respectively);
• make the summaries of certain risks associated with an
investment in the Company in section 1 clearer and more
concise; and
• otherwise improve the accuracy of certain statements made
in the Prospectus and to correct other minor drafting and
cross‑referencing points.
The Company will within 7 days of the date of this Prospectus lodge
an application with the ASX for admission of the Company to the
official list of the ASX and quotation of all Shares (including New
Shares issued pursuant to this Prospectus) on the ASX. Neither ASX
nor ASIC takes any responsibility for the contents of this Prospectus.
The fact that the ASX may admit the Company to its official list is
not to be taken in any way as an indication of the merits of the
Company or the New Shares offered under this Prospectus.
Expiry Date
No Shares will be issued on the basis of this Prospectus later
than 13 months after the date of this Prospectus. Shares offered
pursuant to this Prospectus will be issued on the terms and
conditions set out in this Prospectus.
Note to Applicants
This document is important and should be read in its entirety.
You should read this entire Prospectus carefully before deciding
whether to subscribe for Shares. In particular, you should consider
the risk factors that could affect the performance of the Company
or the value of an investment in the Company, some of which are
outlined in section 6.
The information contained in this Prospectus is not investment
advice and does not take into account your investment objectives,
financial situation, tax position or particular needs. Before deciding
whether to subscribe for Shares, you should consider whether
they are a suitable investment for you in light of your personal
circumstances (including financial and taxation issues) and seek
professional guidance.
Consider risks of investment
It is important that you read this Prospectus carefully and in full
before deciding whether to invest in the Company. In particular,
in considering the prospects of the Company you should consider
the best estimate assumptions underlying any forward‑looking
statement, together with the risk factors that could affect the
Company’s business, financial condition and results of operations,
including macroeconomic and market condition risks. Some of the
key risk factors that should be considered by prospective investors
are set out in section 6 of this Prospectus.
ReNerve Limited Replacement Prospectus
However, there may be risk factors in addition to these that should
be considered in light of your personal circumstances. You should
carefully consider these factors in light of your investment objectives,
financial situation and particular needs (including financial and
taxation issues) and seek professional advice from your accountant,
financial adviser, stockbroker, lawyer or other professional adviser.
Exposure Period
The Corporations Act prohibits the Company from processing the
Applications received until after the Exposure Period. The Exposure
Period is the 7 day period from the date of this Prospectus and may
be extended by ASIC by up to a further 7 days. The purpose of
the Exposure Period is to enable this Prospectus to be examined by
market participants. That examination may result in the identification
of deficiencies in this Prospectus, in which case any Application
received may need to be dealt with in accordance with section 724
of the Corporations Act.
Jurisdiction
This Prospectus and the enclosed Application Form (including any
electronic prospectus) do not constitute an offer in any place in
which, or to any person to whom, it would not be lawful to make
such an offer. In particular, the distribution of this Prospectus in
jurisdictions outside Australia and New Zealand may be restricted
by law and persons who come into possession of this Prospectus
should seek advice on and observe any such restrictions. Any failure
to comply with such restrictions may constitute a violation of
applicable securities laws.
United States
The Shares (including the New Shares) have not been,
and will not be, registered under the US Securities Act 1933
(US Securities Act) and may not be offered or sold in the United
States of America, or to, or for the account or benefit of, any
person in the USA.
Singapore
This document and any other materials relating to the Shares have
not been, and will not be, lodged or registered as a prospectus in
Singapore with the Monetary Authority of Singapore. Accordingly,
this document and any other document or materials in connection
with the offer or sale, or invitation for subscription or purchase, of
Shares, may not be issued, circulated or distributed, nor may the
Shares be offered or sold, or be made the subject of an invitation
for subscription or purchase, whether directly or indirectly, to
persons in Singapore except pursuant to and in accordance with
exemptions in Subdivision (4) Division 1, Part XIII of the Securities
and Futures Act, Chapter 289 of Singapore (SFA), or as otherwise
pursuant to, and in accordance with the conditions of any other
applicable provisions of the SFA. This document has been given
to you on the basis that you are (i) an existing holder of the
Company’s shares, (ii) an “institutional investor” (as defined in
the SFA) or (iii) an “accredited investor” (as defined in the SFA).
In the event that you are not an investor falling within any of the
categories set out above, please return this document immediately.
You may not forward or circulate this document to any other
person in Singapore. Any offer is not made to you with a view to
the Shares being subsequently offered for sale to any other party.
There are on‑sale restrictions in Singapore that may be applicable
to investors who acquire Shares. As such, investors are advised
to acquaint themselves with the SFA provisions relating to resale
restrictions in Singapore and comply accordingly.
Hong Kong
WARNING: This document has not been, and will not be,
registered as a prospectus under the Companies (Winding Up and
Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor
has it been authorised by the Securities and Futures Commission
in Hong Kong pursuant to the Securities and Futures Ordinance
(Cap. 571) of the Laws of Hong Kong (SFO). No action has been
taken in Hong Kong to authorise or register this document or to
permit the distribution of this document or any documents issued
in connection with it. Accordingly, the Shares have not been and
will not be offered or sold in Hong Kong other than to “professional
investors” (as defined in the SFO and any rules made under that
ordinance). No advertisement, invitation or document relating to
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
the Shares has been or will be issued, or has been or will be in the
possession of any person for the purpose of issue, in Hong Kong or
elsewhere that is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted
to do so under the securities laws of Hong Kong) other than with
respect to Shares that are or are intended to be disposed of only
to persons outside Hong Kong or only to professional investors.
No person allotted Shares may sell, or offer to sell, such securities
in circumstances that amount to an offer to the public in Hong Kong
within six months following the date of issue of such securities.
Please see section 4.17 for more details.
The financial information in this Prospectus in section 7 and the
Investigating Accountant’s Report in section 8 have been prepared
for use in Australia.
Form of Prospectus
This Prospectus is posted on https://renerve.com.au (Website).
If you access the electronic version of this Prospectus you should
ensure that you download and read the entire Prospectus.
Any references to documents included on the Website are
provided for convenience only, and none of the documents or
other information on the Website is incorporated by reference
in this Prospectus.
Persons who receive a copy of this Prospectus in its electronic
form may obtain a paper copy of the Prospectus (including any
supplementary document and the Application Form) free of
charge by contacting the Company.
Disclaimer
Investors should not rely on any information about the Company
or the Shares which is not contained in this Prospectus in making
a decision as to whether to acquire Shares under the Offer.
No person is authorised to give any information, or to make any
representation, in connection with the Company or the issue of
Shares which is not contained in this Prospectus. Any information
or representation which is not in this Prospectus may not be relied
on as having been authorised by the Company, the Directors or
any other person in connection with the issue of Shares.
Except as required by law, and then only to the extent so required,
no person warrants or guarantees the future performance of the
Company or any return in relation to a decision made by an
Applicant under this Prospectus.
Speculative investment/dividend policy
The intellectual property assets and business model of the Company
are, as yet, unproven, and an investment in the Company should be
regarded as speculative.
Accordingly, there is no guarantee of the payment of any dividends
or like distributions to successful Applicants by the Company and
the ability to pay any dividends will be dependent on generating
sufficient revenue and profits to support the payment of dividends.
Forward looking statements
The forward‑looking statements in this Prospectus are based
on the Company’s current expectations, estimates, forecasts and
projections about the Company’s business and the industry in
which the Company operates. They are, however, subject to known
and unknown risks, uncertainties and assumptions, many of which
are outside the control of the Company and the Directors and
which could cause actual results, performance or achievements
to differ materially from the expected future results, performance
or achievements expressed or implied by the forward‑looking
statements in this Prospectus. This Prospectus details some
important factors and risks which could cause the Company’s
actual results to differ from the forward‑looking statements
in the Prospectus.
Defined terms and glossary
Capitalised words and expressions used in this Prospectus are
defined in the Glossary at section 12 of this Prospectus.
Financial amounts
Financial amounts in this Prospectus are expressed in Australian
dollars unless otherwise stated. Any discrepancies between totals
and sums of components in tables contained in this Prospectus
are due to rounding.
Photographs and diagrams
Photographs used in this Prospectus which do not have
descriptions are for illustration purposes only and should not
be interpreted to mean that any person shown endorses this
Prospectus or its contents or that the assets shown in them
are owned by the Company. Diagrams used in this Prospectus
are illustrative only and may not be drawn to scale.
Time references
A reference to time in this Prospectus is to Australian Eastern
Daylight Time (AEDT) being the local time in Melbourne,
Australia, unless otherwise stated.
No cooling‑off rights
Cooling‑off rights do not apply to an investment in Shares issued
or transferred under this Prospectus. This means that, in most
circumstances, you cannot withdraw your Application once it
has been accepted.
Privacy
The Company collects information about each Applicant provided
on an Application for the purposes of processing the Application
and, if the Application is successful, to administer the Applicant’s
security holding in the Company. By submitting an Application,
each Applicant agrees that the Company may use the information
provided by that Applicant on that Application for the purposes
set out in this privacy disclosure statement and may disclose it for
those purposes to the Share Registry, the Company’s related bodies
corporate, agents, contractors and third party service providers,
including mailing houses and professional advisers, and to ASX,
ASIC and other regulatory authorities.
If an Applicant becomes a security holder of the Company, the
Corporations Act requires the Company to include information
about the security holder (name, address and details of the
securities held) in its public register. This information must remain
in the register even if that person ceases to be a security holder
of the Company. Information contained in the Company’s register
is also used to facilitate distribution payments and corporate
communications (including the Company’s financial results,
annual reports and other information that the Company may
wish to communicate to its security holders) and compliance
by the Company with legal and regulatory requirements.
If you do not provide the information required on the Application,
the Company may not be able to accept or process your Application.
An Applicant has a right to gain access to the information that the
Company and the Share Registry holds about that person subject
to certain exemptions under law. Access requests must be made
in writing to the Company.
Questions
If you have any questions about how to apply for Shares,
please call your broker or the Share Registry on 1300 288 664.
These forward‑looking statements speak only as at the date
of this Prospectus. Unless required by law, the Company does
not intend to publicly update or revise any forward‑looking
statements to reflect new information or future events.
ReNerve Limited Replacement Prospectus
1
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Contents
Important Notice.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IFC
Chairman’s Letter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1
Investment Highlights. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2
Company Overview. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3
Industry Overview. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
4
Details of the Offer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
5
Board and Management.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
6
Risk Factors.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
7
Financial Information.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
8
Investigating Accountant’s Report.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
9
Intellectual Property Report. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
10 Significant Contracts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
11
Additional Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
12 Glossary.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Corporate Directory. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IBC
2
ReNerve Limited Replacement Prospectus
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Chairman’s Letter
Dear Investor,
The directors of ReNerve Limited (ReNerve or the Company) are delighted to present this Prospectus for
the Initial Public Offer (IPO) of new shares in the Company. We take great pleasure in inviting you to become
a shareholder of ReNerve by participating in the IPO as part of the proposed listing of ReNerve shares on
the Australian Securities Exchange (ASX).
ReNerve focusses on developing bio‑material based medical devices to deliver superior outcomes in the
treatment of peripheral nerve injury (PNI) and related applications. The global market for bio‑material based
devices for the treatment of PNI is growing rapidly from an estimated US$1.68 billion in 2023 to US$6.2 billion
by 2031, representing a compound annual growth rate of 17.8%.
PNIs have serious consequences for patients, including deterioration of motor and sensory function, ongoing
pain, and over the longer term diminished mental health and independence. Unfortunately, patients are poorly
served by the products and surgical procedures that are the current standard of care, many of which were
originally developed for other applications, are not easy for surgeons to use, or deliver sub‑optimal
therapeutic outcomes.
ReNerve aims to deliver significantly better patient outcomes by developing and marketing a comprehensive
portfolio of bio‑material based medical devices specifically designed for PNI treatment. In particular, the devices
have been designed for ease of use in surgery. They are based on bio‑materials that incorporate technology
specifically developed to promote nerve regrowth through providing an optimised, clean and debris‑free
environment, minimising scarring and the negative effects of inflammation.
Our first product, the NervAlign ® Nerve Cuff, has received regulatory clearance from the United States Food
and Drug Authority (FDA) and has been launched in the US market. We have secured product approval for the
NervAlign ® Nerve Cuff in a growing number of US hospitals and seen the cuff used successfully in more than
100 surgical procedures across a range of applications. The NervAlign ® Nerve Cuff has demonstrated excellent
therapeutic outcomes and has received strong endorsement from a number of leading nerve repair surgeons.
The NervAlign ® Nerve Cuff is achieving strong sales growth.
ReNerve is currently developing a portfolio of complementary products for PNI treatment. Some of these
products are based on the same technology as that used in the FDA‑approved NervAlign ® Nerve Cuff, which we
expect will allow us to achieve regulatory approval and get to market at relatively low cost, with modest risk and
in accelerated time frames. In addition, we are developing devices based on our proprietary technology to provide
nerve repair solutions for long length PNI, for which there are currently limited satisfactory solutions.
We will use the proceeds from our IPO to invest in the development and approval of our planned new products
and to fund the sales and marketing initiatives required to aggressively bring those products to market. With a
comprehensive range of medical devices for PNI treatment, we are confident that we will be able to leverage our
existing logistics infrastructure, sales networks, customer base and growing brand recognition in the US market
to achieve further sales growth.
We are motivated by the opportunity to deliver materially improved therapeutic outcomes to patients suffering
from PNI and related nerve damage. We are equally excited about the prospects of building a business that
generates material value for shareholders of ReNerve. We would welcome you as an investor in ReNerve to
share in that value.
Under the IPO, investors are being offered new shares in the Company at a subscription price of $0.20 per share,
to raise a minimum of $5.0 million and up to $7.0 million, as detailed in the Prospectus. Alpine Capital Pty Ltd
has been appointed as Lead Manager to the IPO.
ReNerve is an early‑stage biotech company, which is currently loss making. Therefore, an investment in the
Company is subject to a range of specific risks. For instance, the development of ReNerve’s product portfolio
may be more costly or take more time than expected, or may not achieve the expected clinical endpoints.
Additionally, ReNerve’s new products will require regulatory approvals, in most cases as medical devices,
and rejection, delay or subsequent loss of regulatory approvals could impact the business. Further, ReNerve
is subject to competition from well‑established market participants and, potentially, new market entrants.
These existing and potential competitors may respond to ReNerve’s growth initiatives through aggressive
marketing campaigns or price discounting, or through product improvements or new product introductions.
Finally, ReNerve’s intellectual property strategy (which in part is to rely on confidential know‑how and speed
to market rather than patent protection) may prove sub‑optimal. Please see the IP report in section 9 for further
information regarding the IP specific risks, which we encourage you to read in full. These factors may affect
ReNerve’s market share, sales volumes and margins.
ReNerve Limited Replacement Prospectus
3
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Chairman’s Letter
There are of course general risks associated with an investment in ReNerve, including insufficient funding,
reliance on key personnel, macroeconomic factors, and risks associated with share market investments generally.
A detailed summary of the main risk factors associated with an investment in the Company is set out in
section 6 of the Prospectus. We encourage you to read the Prospectus in full, including the risks outlined
in section 6.
The Closing Date for application and payment for shares under the IPO is 5.00pm AEDT on Friday,
15 November 2024, unless the Maximum Subscription of $7 million is reached earlier, or later as determined
by the Directors.
We look forward to your support and participation in our IPO, and hope to welcome you as a ReNerve
shareholder in the near future.
Yours sincerely
Stephen Cooper
Chairman
4
ReNerve Limited Replacement Prospectus
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
Key Offer Statistics
Offer price
$0.20
Total number of Shares to be issued under the Offer
25,000,000 at Minimum Subscription, and
35,000,000 at Maximum Subscription
Amount to be raised under the Offer
$5,000,000 at Minimum Subscription, and
$7,000,000 at Maximum Subscription
Implied market capitalisation at the Offer price
$26,355,624 at Minimum Subscription, and
$28,355,624 at Maximum Subscription
Indicative Timetable
Event
Date
Lodgement of Prospectus with ASIC
Wednesday, 16 October 2024
Lodgement of Replacement Prospectus with ASIC
Wednesday, 29 October 2024
Opening Date of Offer
Wednesday, 30 October 2024
Closing Date of Offer
Friday, 15 November 2024
Issue of new Shares
Tuesday, 19 November 2024
Expected despatch date of Holding Statements
Tuesday, 19 November 2024
Expected date for Shares to commence trading on ASX
Friday, 22 November 2024
Note: The above dates are indicative only. The Company reserves the right to alter this timetable including the Opening Date of Offer
and the Closing Date of Offer. Applicants are advised to lodge their Application Forms as soon as possible after the Opening Date if
they wish to invest in the Company.
ReNerve Limited Replacement Prospectus
5
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
1Investment
Highlights
6
ReNerve Limited Replacement Prospectus
COLLIER CREATIVE 03 9088 2470
RNL0001 ReNerve IPO_P2d 5 November 2024 3:30 pm
1. Investment Highlights
This section is a summary of key information contained in this Prospectus and is not intended to provide
full information for investors intending to apply for Shares. This Prospectus should be read and considered
in its entirety. The Shares offered under this Prospectus carry no guarantee in respect of return of capital,
return on investment, payment of dividends or their future value.
TOPIC
SUMMARY
MORE INFORMATION
Company Overview
Who is the
Company and
what does it do?
ReNerve Limited ACN 614 848 216 (Company or ReNerve).
See section 2
The Company is focussed on peripheral nerve injury repair.
It develops, commercialises and markets a portfolio of
biomaterial‑based medical devices used in the protection,
repair and/or replacement of peripheral nerves during surgery.
Following United States Food and Drug Administration (FDA)
market clearance for its first product, the NervAlign ® Nerve Cuff,
ReNerve has successfully built a sales and distribution network
and initial customer base in the key US market, which will support
sales across the ReNerve product portfolio. ReNerve is developing
products with an aim of demonstrating superior efficacy and ease
of use through surgical endorsements and published case studies.
ReNerve’s strategy is to develop and commercialise a broader
portfolio of medical devices focussed on nerve repair. It plans
to leverage its demonstrated product development skills,
proven technology and established US‑based logistics and
sales infrastructure to grow its business in the USA, with an
opportunity in the next 12 to 24 months to address other
markets globally.
ReNerve will seek to develop a competitive advantage relative
to other industry participants by developing and marketing
products with superior characteristics in terms of cleanliness,
their ability to promote nerve regeneration and their ease of
surgical use. In particular, ReNerve proposes to deliver better
patient outcomes by developing and selling products that:
(a) protect nerve regrowth from scarring and the negative
effects of inflammation;
(
Share your feedback
Discover